Biotech Acquisition Co (Nasdaq: BIOT) is a blank check company that completed its initial public offering in 2020 and was formed to pursue an acquisition target in the biotechnology and life sciences sector. The company filed a Form 10-Q with the Securities and Exchange Commission on November 17, 2021, reflecting its operational status as a development-stage SPAC during the target-search period. The filing, carrying accession number 0001213900-21-060168, is part of the public record for BIOT's pre-combination activity. Biotech-focused SPACs were among the most active vehicles of that era as sponsors sought targets across drug development, diagnostics, and medical technology. Sign up at SpacDesk for full data on BIOT and the broader SPAC universe.